Immuneel Therapeutics Secures Latest Funding Round

Immuneel Therapeutics secured an undisclosed amount in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Immuneel Therapeutics Raises an undisclosed amount in Funding

Immuneel Therapeutics is a Bengaluru-based Digital Health company focused on Scale CAR-T Therapy.

Investors Behind the Funding

The round was backed by a mix of new, </strong>, Singularity AMC, Rainmatter by Zerodha</strong> · The round also saw participation from, including founder Kiran Mazumdar-Shaw, Eight Roads Ventures. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Immuneel Therapeutics operates in Healthcare & Life Sciences. Immuneel Therapeutics's Series B round shows investors are still backing digital health platforms with real scale narratives. At fresh capital, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

Scale CAR-T Therapy

Looking Ahead

Immuneel Therapeutics Raises Over Rs 100 Crore in Series B to Scale CAR-T Therapy

Source reference: original announcement/article.